skip to Main Content

New Paradigm for drug toxicity


Introducing NEXEL’s History


03. Certification of ISO 9001
05. MOU with Biotoxtech for distribution of NEXEL’s cell products in Japan.
05. In-licensing of iPSC commercialization from Academia Japan (represents Kyoto University)
06. Certification of INNOBIZ


01. Begin domestic sales
04. Participation (Booth) in BioKorea
05. Contract with BOYA medical for distribution of NEXEL’s products in China
05. Obtaining 4 Government Research Fundings (1.4 million dollars)
05. Selection for Institute for military service exception
05. Participation (Booth) in International Korean Society for Biochemistry and Molecular Biology
06. Participation (Booth) in CPhI China
08. MOU with T&R Biofab for 3D Bio-Printing R&D with NEXEL’s cell products
09. Government funding for the development of biotherapeutic (3 million dollars)


02. Certification of venture company (#20160101314)
03. Certification of Research Institute in NEXEL (#2016111120)
05. Sales contract for NEXEL’s products with IMPLAD in China
05. Selection for best value company from Credit Guarantee Fund
06. MOU with Seoulin bio for domestic distribution of NEXEL’s products
09. MOU with Korea Institute of Toxicology (KIT) for drug screening using stem cells
09. Certification of excellent biotechnology from NICE (T6)
11. Contract for transferring cardiomyocyte differentiation technique from KIT
12. Transferring patents from Korea University (Registered: 2, Applicated: 3, PCT: 1)


05. Company name changed as NEXEL, Co., Ltd.
07. Headquarter established at Korea University
07. MoU with Korea University for industry—academia research


09. MOU with Institute of Medicinal Plant Development (IMPLAD) in China
11. Selection for family company in the institute of Animal Molecular biotechnology at Korea University


03. MOU with Anam Hospital at Korea University


09. NEXCELL Bio Established

Back To Top